

奇美醫療財團法人奇美醫院人體試驗委員會
人體研究核准函（新案）



計畫編號：無 / IRB編號: 11411-008

試驗機構：奇美醫療財團法人奇美醫院

計畫主持人：楊清傑 / 協同主持人：無

計畫名稱：利用台灣癌症登記資料庫分析胰臟癌各項預後因子與存活之關聯

計畫書：Version 1, 2025-11-16

受試者同意書：免除告知同意

上述計畫經本院人體試驗委員會於 2025 年 11 月 27 日審查通過，核准執行期限為一年（自 2025 年 11 月 28 日至 2026 年 11 月 27 日），應接受本會之監督，主持人於研究期間所獲得受試者的資料應負保密責任。如試驗無法於核准期限內完成，請於屆期前 2 個月繳交期中報告並申請展延試驗期限，經本會審查核准後方可繼續進行。

Clinical Trial/Research Approval Letter (New Application)

Protocol No.: None / IRB Serial No.: 11411-008

Institute: Chi Mei Medical Center

Principal Investigator: Ching-Chieh Yang / Sub-Investigator(s): None

Protocol Title: Analysis of Cancer Registry Data on Survival and Related Prognostic Factors
among Pancreatic Cancer Patients in Taiwan.

Protocol Version and Date: Version 1, 2025-11-16

Informed Consent Form: Waiver of Informed Consent

The study was approved by the Institutional Review Board of the Chi Mei Medical Center on 27 Nov 2025 and will be monitored by the IRB. The duration of this approval is one year (from 28 Nov 2025 until 27 Nov 2026). Investigators are responsible for keeping the subject information confidential. The principal investigator is required to submit an Annual Report 2 months before the expiry date for continuing review approval in order for the research to proceed.

人體試驗委員會

主任委員：邢中熹



2025 年 11 月 27 日

Yours sincerely,

Hsing, Chung-Hsi M.D.

Chairman

Institutional Review Board,

Chi Mei Medical Center, Tainan, Taiwan

本會組織與執行皆符合 ICH-GCP

The Institutional Review Board performs its functions according to written operating procedures
and complies with GCP and with the applicable regulatory requirements.